Tyler Young, Industrials Investment Executive, Named CD&R Partner
Since joining CD&R in 2011, Tyler has contributed to building the Firm's Industrials vertical, expanding CD&R's presence within the building products and industrial distribution sectors. Tyler brings deep industry knowledge and relationships in these markets, where he has been actively involved in sourcing and evaluating numerous opportunities. He has played a key role in the Firm's investments in Cornerstone Building Brands, Foundation Building Materials, SunSource, White Cap and Wilsonart and has served on the board of directors at all of these companies.
Tyler started his career in the investment banking division of Bank of America Merrill Lynch before joining CD&R as an Associate and later held corporate development and business operations positions at PayPal and LinkedIn, respectively. He earned an M.B.A. from Harvard Business School and a B.A. from Dartmouth College.
"Tyler's appointment is a testament to the value he brings to CD&R, both as a strategic thinker and a collaborative leader," said
About CD&R
Founded in 1978, CD&R is a leading private investment firm with a strategy of generating strong investment returns by building more robust and sustainable businesses through the combination of skilled investment experience and deep operating capabilities. In partnership with the management teams of its portfolio companies, CD&R takes a long-term view of value creation and emphasizes positive stewardship and impact. The firm invests in businesses that span a broad range of industries, including industrial, healthcare, consumer, technology and financial services end markets. CD&R is privately owned by its partners and has offices in
Contact:
212 407 5200
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/tyler-young-industrials-investment-executive-named-cdr-partner-302642978.html
SOURCE Clayton, Dubilier & Rice
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kowa Pharmaceuticals America Announces FDA Acceptance of New Drug Application for K-911, an Investigational IOP-Lowering Eye Drop for Patients with Open-Angle Glaucoma or Ocular Hypertension
- Connecting clinical knowledge with care delivery: NCODA and Cureety partner to bring trusted regimen guidance at the point of care
- Postquant Labs Launches the First Quantum Cross-Chain Swaps
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Twitter, BofA/Merrill LynchSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share